Bone health in cancer: ESMO Clinical Practice Guidelines

•The clinical course of advanced cancer for many patients with bone metastases can be transformed through optimum multidisciplinary management.•Bone-targeted agents significantly reduce skeletal morbidity in patients with bone metastases across tumour types and should be part of standard treatment.•Treatment-induced bone loss increases fracture risk and may require use of a bone-targeted agent in addition to lifestyle modifications.•The addition of a bisphosphonate to standard adjuvant therapies for postmenopausal early breast cancer reduces bone recurrence and improves survival.

• A
  Amgen
• BS
  Bristol-Myers Squibb
• EL
  Eli Lilly and Company
• P
  Pfizer
• A
  AstraZeneca
• S
  Sanofi
• PU
  Purdue University
• C
  Celgene
• GH
  Genomic Health
• E
  Eisai
• AP
  Astellas Pharma
• ES
  European Society for Medical Oncology
• S
  Servier
• I
  Ipsen
• SM
  Sirtex Medical